2) This study is still only a small-scale study, which may not be enough to fully explain the effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin for ovarian cancer patients. This evidence concerns the gene CX3CL1 and ovarian cancer.